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Clopidogrel in ESRD patients with
acute coronary syndrome
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Surana et al.1 describe a male patient admitted with a
provisional diagnosis of non-ST-elevation myocardial infarc-
tion. The authors state that the patient did not receive
clopidogrel because of substantial comorbidities. I disagree
with this approach. Clopidogrel, 300mg loading dose
followed by 75mg daily, should be added to aspirin in a
patient with unstable angina/non-ST-elevation myocardial
infarction.2,3 Even if a patient has a history of gastrointestinal
bleeding, clopidogrel plus aspirin can be administered with
proton pump inhibitors to minimize the risk of recurrent
gastrointestinal bleeding.2 Although the dialysis population is
usually excluded from trials in coronary artery disease,4 no
dosage adjustment is required for clopidogrel in a patient
with renal impairment.3
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To the Editor: In a recent interesting review regarding
etiologic mechanisms of stone formation,1 no mention was
made of the role of medullary sponge kidney (MSK),
characterized by ectasia and cystic formation in the medul-
lary collecting precalyceal ducts.
Recent findings and its association with different mal-
formative conditions suggest that MSK belongs to the category
of developmental disorder, resulting from the disruption of the
ureteric bud/metanephric-blastema interface, as evidenced by
the occasional presence of embryonal tissue in the affected
papillae.2 In addition to anatomic abnormalities, low levels
of urinary inhibitors of stones (citrate and magnesium)
and alterations of tubular handling of bicarbonate/calcium/
http://www.kidney-international.org l e t t e r to the ed i to r
& 2009 International Society of Nephrology
a
b c
d
Medullary collecting
precalyceal ducts
Tubular ectasia
Microcrystals
Cysts
Figure 1 | Stone formation in MSK. Scheme showing the typical urographic appearance of ‘pyramidal-blush/paint brush’ in the case
of (a) medullary sponge kidneys corresponding to the presence of (b) dilated precalyceal collecting ducts (c) with some cysts and
(d) ectasic areas of tubular structures well evident at light microscopy, which offer a favorable setting for crystal deposition.
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potassium have also been shown in patients with MSK,
potentially contributing to the pathogenesis of nephrolithiasis.3
This renal malformation is frequently associated with
nephrocalcinosis and renal stones. In particular, MSK is
associated with a 60% lifetime risk of renal stones, and the
prevalence of MSK in patients with renal stones is
significantly higher (8.5%, Po0.01) than in the control
population (1.5%).4
As MSK was diagnosed only after the introduction of
intravenous urography in the 1930s (Figure 1), and
conventional computed tomography, which has been pre-
ferred since the mid-1990s, is not satisfactory for unmasking
MSK, except when using multidetector-row computed
tomography of high-resolution three-dimensional displays
and late urographic images, ‘there is a concrete possibility of
this renal condition being forgotten in the future.’2 Therefore,
it seems to be even more mandatory not to miss MSK in
reviews of renal stones.
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I agree with Stratta et al.1 that the association of various
malformative disorders with medullary sponge kidney
(MSK) is interesting, yet challenging. These various asso-
ciations have led to the hypothesis that embryological
nephronal maldevelopment may participate in the patho-
genesis of this disease.2 However, as stated in a very recent
article published in this journal, the pathogenesis of MSK
has not yet been fully elucidated.2 Although multiple
candidate genes have been proposed to play a role in the
process of embryological development, none have been
revealed to be directly involved in uteric-bud/metanephric-
blastema interface disruption.3–5 This notion is supported
by a study on the kidneys of pre-term infants show-
ing an abundance of calcification-promoting molecules,
specifically osteopontin and hyaluronan, expressed at the
luminal side of the renal tubular differentiating cells.6
There was no mention made of the role of MSK in
my recent paper7 because the true advancement in this
field needs to be substantiated. This could be achieved by
direct tissue examination of the renal papillary structure
in affected patients for both the presence of undifferen-
tiated embryonal tissue and for the expression of various
potential genes participating in nephronal development.
The metabolic abnormalities that were mentioned by
Stratta et al.1 are only associations that may contribute
to kidney stone formation but are not causal in the
pathogenesis of this disease.8
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To the Editor: It is with interest that we read the report
of Sun et al.1 on how hypoxia-inducible factor-1a (HIF-1a)
induces TWIST1 expression in human tubule cell lines,
providing a model for hypoxia-induced renal fibrosis. Their
findings complement two earlier papers linking hypoxic
signaling to TWIST1 expression. In a functional screen in
Caenorhabditis elegans, TWIST1 was identified as a HIF
target, and in human cancer cells, hypoxia induces TWIST1
expression and epithelial–mesenchymal transition.2–4 Impor-
tantly, silencing of TWIST1 attenuates metastatic cancer
outgrowth in xenograft models.4 Taken together, these
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